Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Among patients with acute myeloid leukemia undergoing allogeneic transplantation from matched siblings or unrelated donors who received post-transplant cyclophosphamide plus calcineurin inhibitor (CNI; tacrolimus or cyclosporine A) plus mycophenolate mofetil (PTCy/TAC or CSA/MMF) or anti-thymocyte globulin plus CNI (tacrolimus or cyclosporine A) plus methotrexate (ATG/TAC or CSA/MTX), no statistically significant differences were observed in the incidence of acute GVHD grade II–IV and III–IV or 2-year total and extensive chronic GVHD between the groups.